The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Open accessAbstract
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS: We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. RESULTS: Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). CONCLUSIONS: Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of adverse events well after the market entry of major drugs such as rofecoxib and rosiglitazone. [36,37]”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“a well-publicized meta-analysis of small phase 3 trials suggesting an increase in myocardial ischemic events (odds ratio, 1.43 [95% CI, 1.03–1.98])”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [210]
In the citing paper
“Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Research works printed but not linked: 1
- 10.1210/jc.86.1.280 · DOI
Cited by
Sorted by citations
Items 501–600 of 1,024
Obesity: Pathophysiology and Clinical Management
Gurevich-Panigrahi, T., Panigrahi, S., Wiecheć, E., & Łoś, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787315568 · Cited by 111
Medical reversal: why we must raise the bar before adopting new technologies.
Prasad, V. K., & Cifu, A. S. (2011) · Europe PMC (PubMed Central) · Cited by 106
Anagnostis, P. G., Katsiki, N., Adamidou, F., Athyros, V. G., Karagiannis, A. I., Kita, M. D., & Mikhailidis, D. P. (2012) · Metabolism · doi:10.1016/j.metabol.2012.05.002 · Cited by 107
Vitale, S. G., Laganà, A. S., Nigro, A., Rosa, V. L. L., Rossetti, P., Rapisarda, A. M. C., Vignera, S. L., Condorelli, R. A., Corrado, F., Buscema, M., et al. (2016) · PPAR Research · doi:10.1155/2016/6517313 · Cited by 106
An overview of ferroptosis in non-alcoholic fatty liver disease
Wang, S., Liu, Z., Geng, J., Li, L., & Feng, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113374 · Cited by 108
Crystallographic Studies of Human MitoNEET
Hou, X., Liu, R., Ross, S. A., Smart, E. J., Zhu, H., & Gong, W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700172200 · Cited by 107
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
An update on the pharmacological management of endometriosis
Streuli, I., de Ziegler, D., Santulli, P., Marcellin, L., Borghese, B., Batteux, F., & Chapron, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.767334 · Cited by 109
Bolli, G. B., Dotta, F., Colin, L., Minic, B., & Goodman, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01023.x · Cited by 105
Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective
Cui, J., Liu, Y., Li, Y. H., Xu, F., & Liu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.644189 · Cited by 112
Diabetes and bone health: the relationship between diabetes and osteoporosis‐associated fractures
Kurra, S., & Siris, E. S. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1197 · Cited by 106
Lea, S., Plumb, J., Metcalfe, H. J., Spicer, D., Woodman, P., Fox, J. C., & Singh, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00187812 · Cited by 105
VILAR GOMEZ, E., RODRIGUEZ DE MIRANDA, A., GRA ORAMAS, B., ARUS SOLER, E., LLANIO NAVARRO, R., CALZADILLA BERTOT, L., YASELLS GARCIA, A., & DEL ROSARIO ABREU VAZQUEZ, M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04122.x · Cited by 105
The Importance of Clinical Trial Data Sharing: Toward More Open Science
Ross, J. S., Lehman, R., & Gross, C. P. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965798 · Cited by 104
Xie, S., Lee, Y.-F., Kim, E., Chen, L.-M., Ni, J., Fang, L., Liu, S., Lin, S.-J., Abe, J., Berk, B. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905724106 · Cited by 104
Rehman, M. B., Tudrej, B. V., Soustre, J., Buisson, M., Archambault, P., Pouchain, D., Vaillant-Roussel, H., Gueyffier, F., Faillie, J., Pérault-Pochat, M.-C., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.09.005 · Cited by 105
Engler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 103
Association between serious ischemic cardiac outcomes and medications used to treat diabetes
Margolis, D. J., Hoffstad, O., & Strom, B. L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1630 · Cited by 104
Rosiglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006063.pub2 · Cited by 106
Thiazolidinediones Regulate Adipose Lineage Dynamics
Tang, W., Zeve, D., Seo, J. H., Jo, A.-Y., & Graff, J. M. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.05.012 · Cited by 108
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia–reperfusion injury
Chinda, K., Palee, S., Surinkaew, S., Phimphilai, M., Chattipakorn, S. C., & Chattipakorn, N. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.011 · Cited by 103
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 124
Mandema, J. W., Gibbs, M., Boyd, R. A., Wada, D., & Pfister, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.242 · Cited by 104
Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
Mannucci, E., Monami, M., Lamanna, C., Gensini, G., & Marchionni, N. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00892.x · Cited by 103
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W. J. C., Garcia-Garcia, H., van Es, G., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.881003 · Cited by 102
He, J., Chen, L.-X., & Li, H. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.02.033 · Cited by 102
End Points for Clinical Trials in Acute Heart Failure Syndromes
Allen, L. A., Hernandez, A. F., O’Connor, C. M., & Felker, G. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.079 · Cited by 107
Fidan, E., Ersöz, H. Ö., Yılmaz, M., Yilmaz, H., Koçak, M., Karahan, C., & Erem, C. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0276-y · Cited by 102
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Adipose tissue inflammation in glucose metabolism
Kammoun, H. L., Kraakman, M. J., & Febbraio, M. A. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9274-4 · Cited by 101
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Ruzehaji, N., Frantz, C., Ponsoye, M., Avouac, J., Pezet, S., Guilbert, T., Luccarini, J., Broqua, P., Junien, J., & Allanore, Y. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208029 · Cited by 103
Genome Editing of Pigs for Agriculture and Biomedicine
Yang, H., & Wu, Z. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00360 · Cited by 103
The RISE Consortium (2013) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 101
Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., Anagnostis, P. G., Mikhailidis, D. P., Fiorino, G., Rovida, S., Correale, C., Malesci, A., & Danese, S. (2009) · Current Drug Targets · doi:10.2174/138945010790030992 · Cited by 102
PPARγand Its Role in Cardiovascular Diseases
Chandra, M., Miriyala, S., & Panchatcharam, M. (2017) · PPAR Research · doi:10.1155/2017/6404638 · Cited by 101
Minimizing Bias in Randomized Trials
Psaty, B. M., & Prentice, R. L. (2010) · JAMA · doi:10.1001/jama.2010.1161 · Cited by 100
A Practical “ABCDE” Approach to the Metabolic Syndrome
Blaha, M. J., Bansal, S., Rouf, R., Golden, S. H., Blumenthal, R. S., & DeFilippis, A. P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.932 · Cited by 96
Mode of Peroxisome Proliferator-Activated Receptor γ Activation by Luteolin
Puhl, A. C., Bernardes, A., Silveira, R. L., Yuan, J., Campos, J. C. L. D. O., Saidemberg, D. M., Palma, M. S., Čvoro, A., Ayers, S. D., Webb, P., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076216 · Cited by 100
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs
Binda, C., Aldeco, M., Geldenhuys, W. J., Tortorici, M., Mattevi, A., & Edmondson, D. E. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200196p · Cited by 100
The effects of cardiovascular risk factors on cognitive compromise
Beeri, M. S., Ravona‐Springer, R., Silverman, J. M., & Haroutunian, V. H. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/msbeeri · Cited by 101
Everaert, B., Craenenbroeck, E. M. V., Hoymans, V. Y., Haine, S. E. F., Nassauw, L. V., Conraads, V. M., Timmermans, J., & Vrints, C. J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.018 · Cited by 100
Reddy, K. J., Singh, M., Bangit, J. R., & Batsell, R. R. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328333645a · Cited by 103
KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke
Yin, K., Fan, Y., Hamblin, M., Zhang, J., Zhu, T., Li, S., Hawse, J. R., Subramaniam, M., Song, C.-Z., Urrutia, R. A., et al. (2013) · Brain · doi:10.1093/brain/awt002 · Cited by 99
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 99
Barber, T. M., Adams, E. F., Ansorge, O., Byrne, J. V., Karavitaki, N., & Wass, J. A. H. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0466 · Cited by 98
Therapy development in Huntington disease: From current strategies to emerging opportunities
Dickey, A. S., & Spada, A. R. L. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38494 · Cited by 103
SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes
Wu, X., Liu, H., Brooks, A. C., Xu, S., Luo, J., Steiner, R., Mickelsen, D. M., Moravec, C. S., Alexis, J. D., Small, E. M., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.318988 · Cited by 98
Meta-analysis of incidence of rare events
Lane, P. W. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280211432218 · Cited by 98
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B. H., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R. W., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis
Duijnhoven, R. G., Straus, S. M. J. M., Raine, J. M., de Boer, A., Hoes, A. W., & Bruin, M. L. D. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001407 · Cited by 97
Adipocyte-specific loss of PPARγ attenuates cardiac hypertrophy
Fang, X., Stroud, M. J., Ouyang, K., Li, F., Zhang, J., Dalton, N. D., Gu, Y., Wu, T., Peterson, K. L., Huang, H., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89908 · Cited by 97
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
Williams, D. M., Jones, H. F., & Stephens, J. W. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 99
Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study
Rasgon, N., Kenna, H. A., Williams, K. E., Powers, B. N., Wroolie, T., & Schatzberg, A. F. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.32 · Cited by 97
Mechanisms by which diabetes increases cardiovascular disease
Gleissner, C. A., Galkina, E., Nadler, J. L., & Ley, K. F. (2007) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2007.12.005 · Cited by 99
Giles, T. D., Miller, A. B., Elkayam, U., Bhattacharya, M., & Pérez, A. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.02.007 · Cited by 97
Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms
Jones, A., Deb, R., Torsney, E., Howe, F. A., Dunkley, M., Gnaneswaran, Y., Gaze, D. C., Nasr, H. H., Loftus, I. M., Thompson, M. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.852467 · Cited by 101
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 102
Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 96
Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice
Chan, S. Y., & Rubin, L. J. (2017) · European Respiratory Review · doi:10.1183/16000617.0094-2017 · Cited by 101
Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Fukushima, A., Milner, K., Gupta, A. K., & Lopaschuk, G. D. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710150445 · Cited by 98
Jain, M. R., Giri, S. R., Trivedi, C. J., Bhoi, B., Rath, A., Vanage, G. R., Vyas, P., Ranvir, R. K., & Patel, P. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.136 · Cited by 96
Lorgunpai, S. J., Grammas, M., Lee, D. S. H., McAvay, G., Charpentier, P. A., & Tinetti, M. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089447 · Cited by 97
Nuclear receptors as drug targets for metabolic disease
Schulman, I. G. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.002 · Cited by 95
Drug Repositioning for Diabetes Based on 'Omics' Data Mining
Zhang, M., Luo, H., Xi, Z., & Rogaeva, E. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126082 · Cited by 96
Pharmacogenetics of Anti-Diabetes Drugs
DiStefano, J. K., & Watanabe, R. M. (2010) · Pharmaceuticals · doi:10.3390/ph3082610 · Cited by 96
Ramot, Y., Mastrofrancesco, A., Camera, E., Desreumaux, P., Paus, R., & Picardo, M. (2015) · Experimental Dermatology · doi:10.1111/exd.12647 · Cited by 95
Differing Effects of Metformin on Glycemic Control by Race-Ethnicity
Williams, L. K., Padhukasahasram, B., Ahmedani, B. K., Peterson, E. L., Wells, K. E., Burchard, E. G., & Lanfear, D. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1539 · Cited by 96
Statistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 98
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 98
Elley, C. R., Kenealy, T. W., Robinson, E., & Drury, P. L. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02581.x · Cited by 97
Insulin resistance protects the heart from fuel overload in dysregulated metabolic states
Taegtmeyer, H., Beauloye, C., Harmancey, R., & Hue, L. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00854.2012 · Cited by 97
Recent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbccf2 · Cited by 94
Novel aspects of postprandial lipemia in relation to atherosclerosis
Alipour, A., Elte, J. W. F., van Zaanen, H. C. T., Rietveld, A. P., & Cabezas, M. C. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.007 · Cited by 94
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Newman, J. D., Vani, A. K., Alemán, J. O., WEINTRAUB, H. S., Berger, J. S., & Schwartzbard, A. Z. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.071 · Cited by 95
Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature
Oppi, S., Nusser‐Stein, S., Błyszczuk, P., Wang, X., Jomard, A., Marzolla, V., Yang, K., Velagapudi, S., Ward, L. J., Yuan, X., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz667 · Cited by 95
Metabolic Aspects of Anthracycline Cardiotoxicity
Russo, M., Sala, A. D., Tocchetti, C. G., Porporato, P. E., & Ghigo, A. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00812-1 · Cited by 100
PPAR-γ Agonists and Their Role in Type 2 Diabetes Mellitus Management
Bermúdez, V., Finol, F., Parra, N., Parra, M., Pérez, A., Peñaranda, L., Vílchez, D., Rojas, J., Arráiz, N., & Velasco, M. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181c08081 · Cited by 96
Ceylan‐Isik, A. F., Fliethman, R., Wold, L. E., & Ren, J. T. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241142 · Cited by 94
The Role of PPARγ in Cardiovascular Diseases
Kvandová, M., Majzúnová, M., & Dovinová, I. (2016) · Physiological Research · doi:10.33549/physiolres.933439 · Cited by 95
The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health
Brody, H. A., & Light, D. W. (2011) · American Journal of Public Health · doi:10.2105/ajph.2010.199844 · Cited by 93
Wallach, J. D., Wang, K., Zhang, A. D., Cheng, D., Nardini, H. K. G., Lin, H., Bracken, M. B., Desai, M. M., Krumholz, H. M., & Ross, J. S. (2020) · BMJ · doi:10.1136/bmj.l7078 · Cited by 94
Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association
Solal, A. C., Beauvais, F., & Logeart, D. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.04.001 · Cited by 94
TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis
Fujisawa, K., Nishikawa, T., Kukidome, D., Imoto, K., Yamashiro, T., Motoshima, H., Matsumura, T., & Araki, E. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.141 · Cited by 97
Landgraf, R. R., Chalmers, M. J., & Griffin, P. R. (2011) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-011-0298-2 · Cited by 92
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2019) · Cells · doi:10.3390/cells8070726 · Cited by 94
Lee, W. S., & Kim, J. (2015) · PPAR Research · doi:10.1155/2015/271983 · Cited by 97
Beyer, A., de Lange, W. J., Halabi, C. M., Modrick, M. L., Keen, H. L., Faraci, F. M., & Sigmund, C. D. (2008) · Circulation Research · doi:10.1161/circresaha.108.176339 · Cited by 92
Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention?
Luchsinger, J. A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091687 · Cited by 91
Future Perspective of Diabetic Animal Models
Pandey, S., & Dvorakova, M. C. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190626143832 · Cited by 100
A Comparison of the Empirical Performance of Methods for a Risk Identification System
Ryan, P. B., Stang, P., Overhage, J. M., Suchard, M. A., Hartzema, A. G., DuMouchel, W., Reich, C., Schuemie, M. J., & Madigan, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0108-9 · Cited by 96
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
The rise and fall of rosiglitazone
Nissen, S. E. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq016 · Cited by 91
Self-citationEmerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Morgan, C. L., Poole, C., Evans, M., Barnett, A. H., Jenkins‐Jones, S., & Currie, C. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3034 · Cited by 90
Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
Paglialunga, S., & Dehn, C. A. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0321-5 · Cited by 93
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 92
Thiazolidinedione‐induced skeletal fragility – mechanisms and implications
Grey, A. B. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00931.x · Cited by 89
Chodavarapu, H., Grobe, N., Somineni, R. P., Salem, E., Madhu, M. N., & Elased, K. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062833 · Cited by 90
Metadata
- Authors
- Nissen, S. E., & Wolski, K.
- Affiliations
- Cleveland Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2457-2471
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127125241
- Semantic Scholar
- 238422dc26dc6a78cb2b03fad835d7d1f1f95edb
- Cited by
- 4,675
- References
- 29
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 89 · 2023: 117 · 2022: 132 · 2021: 169 · 2020: 175 · 2019: 198 · 2018: 213 · 2017: 222 · 2016: 234 · 2015: 218 · 2014: 259 · 2013: 271 · 2012: 295
- FWCI
- 395.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- New England Journal of Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, myocardial infarction, cardiovascular mortality, type 2 diabetes, thiazolidinediones, drug safety, HbA1c
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Middle Aged, Myocardial Infarction, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
